219 related articles for article (PubMed ID: 24805801)
1. Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.
Vandael E; Marynissen T; Reyntens J; Spriet I; Vandenberghe J; Willems R; Foulon V
Int J Clin Pharm; 2014 Aug; 36(4):757-65. PubMed ID: 24805801
[TBL] [Abstract][Full Text] [Related]
2. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
Das B; Rawat VS; Ramasubbu SK; Kumar B
Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.
Khan Q; Ismail M; Haider I; Khan F
Int J Clin Pharm; 2017 Dec; 39(6):1256-1264. PubMed ID: 28895028
[TBL] [Abstract][Full Text] [Related]
4. [Drug-drug interactions with risk of QT-prolongation. A epidemiological study in Belgian community pharmacies].
Vandael E; De WuLf I; Foulon V
J Pharm Belg; 2016 Dec; (4):14-23. PubMed ID: 30281244
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients.
Hefner G; Hahn M; Hiemke C; Toto S; Wolff J; Roll SC; Klimke A
J Neural Transm (Vienna); 2021 Feb; 128(2):243-252. PubMed ID: 33417009
[TBL] [Abstract][Full Text] [Related]
6. Leading 20 drug-drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients.
Das B; Ramasubbu SK; Agnihotri A; Kumar B; Rawat VS
Ther Adv Cardiovasc Dis; 2021; 15():17539447211058892. PubMed ID: 34841978
[TBL] [Abstract][Full Text] [Related]
7. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
[TBL] [Abstract][Full Text] [Related]
8. Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany.
Elsayed M; Abdel-Kahaar E; Gahr M; Connemann BJ; Denkinger M; Schönfeldt-Lecuona C
Eur J Clin Pharmacol; 2021 May; 77(5):767-775. PubMed ID: 33230596
[TBL] [Abstract][Full Text] [Related]
9. Frequency of high-risk use of QT-prolonging medications.
Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
[TBL] [Abstract][Full Text] [Related]
10. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N
Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
[TBL] [Abstract][Full Text] [Related]
12. The role of QT-prolonging medications in a forensic autopsy study from Western Denmark.
Ahmed H; Larsen MK; Hansen MR; Andersen CU
Forensic Sci Int; 2021 Aug; 325():110889. PubMed ID: 34225211
[TBL] [Abstract][Full Text] [Related]
13. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of QT-Prolonging Drug-Drug Interactions in Psychiatry: A Systematic Review and Meta Analysis.
Ramasubbu SK; Mishra A; Mandal S
J Pharm Pract; 2024 Feb; 37(1):162-168. PubMed ID: 35968552
[No Abstract] [Full Text] [Related]
15. Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs.
Pezo RC; Yan AT; Earle C; Chan KK
Heart; 2019 Nov; 105(21):1649-1655. PubMed ID: 31129611
[TBL] [Abstract][Full Text] [Related]
16. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience.
De Ponti F; Poluzzi E; Montanaro N
Eur J Clin Pharmacol; 2000 Apr; 56(1):1-18. PubMed ID: 10853872
[TBL] [Abstract][Full Text] [Related]
17. [QTc-prolonging drugs and the risk of sudden death].
Reingardiene D; Vilcinskaite J
Medicina (Kaunas); 2007; 43(4):347-53. PubMed ID: 17485963
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
Khan Q; Ismail M; Haider I; Ali Z
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units.
Khan Q; Ismail M; Haider I
Postgrad Med; 2018 Nov; 130(8):660-665. PubMed ID: 30145917
[TBL] [Abstract][Full Text] [Related]
20. QTc prolongation with antipsychotics: is routine ECG monitoring recommended?
Shah AA; Aftab A; Coverdale J
J Psychiatr Pract; 2014 May; 20(3):196-206. PubMed ID: 24847993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
